LOS ANGELES, April 15 /PRNewswire-FirstCall/ -- Delivering on its commitment to relentless progress in cancer care; Lilly Oncology will present 17 studies at the 2007 American Association for Cancer Research (AACR) Annual Meeting in Los Angeles from April 14-18, 2007. Many of the studies -- which investigate ALIMTA® (pemetrexed for injection); GEMZAR® (gemcitabine HCl for injection), enzastaurin and other products in Lilly’s pipeline are aimed at utilizing pharmacogenomic information such as biomarkers to enhance treatment and improve patient outcomes. Biomarkers are genetic indicators that help predict how patients will respond to certain therapies.
